Taner Damci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Taner Damci has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Emre Durcan
Division of Endocrinology and Metabolic Diseases, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey
2 shared publications - Mustafa Sait Gonen
Department of Endocrinology, Metabolism, and Diabetes, Istanbul University-Cerrahpasa, Istanbul, Turkey
2 shared publications - Serdar Sahin
Division of Endocrinology and Metabolism, Department of Internal Medicine, İstanbul University-Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye
2 shared publications - Banu Betul Kocaman
Department of Endocrinology and Metabolism, Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Istanbul, Turkey
1 shared publication - Burcu Saglamer1 shared publication
- Busenur Gönen
Department of Ophthalmology, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye
1 shared publication
Latest Publications
- Open Access
- 8 December 2025
- Published by AVES YAYINCILIK A.Ş. in Cerrahpasa Medical Journal
- Vol. 49, 1-4
A Simple Reminder that Increases Levels of Physical Activity and Improves Glycemic Control in Patients with Type 2 Diabetes
Objective: Daily step count is widely accepted as a valuable indicator of physical activity level. The study aimed to test whether it was possible to establish and/or increase patients' connectedness with the pedometer data in their smartphones and smartwatches through a short reminder. Methods: The study included 70 patients whose daily average step count was checked, who provided good glycemic control and whose treatment would not be changed (HbA1c < 7.5%). Demographic and laboratory data of the patients, average step counts in the last 6 months, and smartphone models were recorded, and these data were compared with the data after 6 months. Results: The study included 70 diabetic patients, 30 women and 40 men. The mean number of steps increased from 5587.8 plus/minus 2959 at baseline to 6219 plus/minus 3001 after 6 months. The number of steps increased from 4692 plus/minus 2402 to 6502 plus/minus 2813 in 47 (62%) patients with brief reminder (P < .001). There is a correlation between the increase in the number of steps and the decrease in HbA1c (P < .05). Conclusion: This study demonstrates that a short reminder recited by physicians during the diabetes outpatient clinics visits aimed at increasing connectedness to smartphone/watch daily step count data leads to an increase in daily step count in most of the patients over 6 months. The increase in the daily step count correlated significantly with a decrease in HbA1c levels.
- 8 December 2025
- Published by AVES YAYINCILIK A.Ş. in Cerrahpasa Medical Journal
- Vol. 49, 1-4
Open AccessA Simple Reminder that Increases Levels of Physical Activity and Improves Glycemic Control in Patients with Type 2 Diabetes
Objective: Daily step count is widely accepted as a valuable indicator of physical activity level. The study aimed to test whether it was possible to establish and/or increase patients' connectedness with the pedometer data in their smartphones and smartwatches through a short reminder. Methods: The study included 70 patients whose daily average step count was checked, who provided good glycemic control and whose treatment would not be changed (HbA1c < 7.5%). Demographic and laboratory data of the patients, average step counts in the last 6 months, and smartphone models were recorded, and these data were compared with the data after 6 months. Results: The study included 70 diabetic patients, 30 women and 40 men. The mean number of steps increased from 5587.8 plus/minus 2959 at baseline to 6219 plus/minus 3001 after 6 months. The number of steps increased from 4692 plus/minus 2402 to 6502 plus/minus 2813 in 47 (62%) patients with brief reminder (P < .001). There is a correlation between the increase in the number of steps and the decrease in HbA1c (P < .05). Conclusion: This study demonstrates that a short reminder recited by physicians during the diabetes outpatient clinics visits aimed at increasing connectedness to smartphone/watch daily step count data leads to an increase in daily step count in most of the patients over 6 months. The increase in the daily step count correlated significantly with a decrease in HbA1c levels.
- Open Access
- 30 April 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (2) , 735-742
Does treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?
To evaluate the impact of treatment with Sodium-Glucose Co-transporter-2 (SGLT2) Inhibitors on quality of life (QoL), sleep quality (SQ) and anxiety levels in patients with Type 2 Diabetes Mellitus (T2DM). Ninety-seven patients with type 2 diabetes admitted to tertiary care hospital diabetes clinic were included. Fifty patients were randomized to receive SGLT2 inhibitors in addition to baseline treatment (Group A), 47 subjects continued with their baseline treatment or were added other medications as needed (Group B). Thirty healthy controls (HC) were recruited (Group C). All groups were subjected to the Turkish version of Short Form-36 (SF-36), Pittsburgh Sleep Quality (PSQ), and Beck Anxiety Inventory (BAI) scales both at baseline and final visit. Physical function, emotional role limitation, vitality, mental health, pain, general health perception scores of SF-36 were significantly improved in Group A, at the end of the follow-up period. There was no significant change in terms of PSQ, BAI scores and hypoglycaemia documented in all groups. The intervention-related change in HbA1c level, body weight and body mass index were significantly higher in Group A. The QoL was improved in people with diabetes who were taking SGLT2 inhibitors. This may be explained by weight loss observed in participants.
- 30 April 2021
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 51 (2) , 735-742
Open AccessDoes treatment with sodium-glucose co-transporter-2 inhibitors have an effect on sleep quality, quality of life, and anxiety levels in people with Type 2 diabetes mellitus?
To evaluate the impact of treatment with Sodium-Glucose Co-transporter-2 (SGLT2) Inhibitors on quality of life (QoL), sleep quality (SQ) and anxiety levels in patients with Type 2 Diabetes Mellitus (T2DM). Ninety-seven patients with type 2 diabetes admitted to tertiary care hospital diabetes clinic were included. Fifty patients were randomized to receive SGLT2 inhibitors in addition to baseline treatment (Group A), 47 subjects continued with their baseline treatment or were added other medications as needed (Group B). Thirty healthy controls (HC) were recruited (Group C). All groups were subjected to the Turkish version of Short Form-36 (SF-36), Pittsburgh Sleep Quality (PSQ), and Beck Anxiety Inventory (BAI) scales both at baseline and final visit. Physical function, emotional role limitation, vitality, mental health, pain, general health perception scores of SF-36 were significantly improved in Group A, at the end of the follow-up period. There was no significant change in terms of PSQ, BAI scores and hypoglycaemia documented in all groups. The intervention-related change in HbA1c level, body weight and body mass index were significantly higher in Group A. The QoL was improved in people with diabetes who were taking SGLT2 inhibitors. This may be explained by weight loss observed in participants.
- Open Access
- 31 December 2017
- Published by ClinMed International Library in International Archives of Endocrinology Clinical Research
- Vol. 3 (1)
Serum Level of Cytokeratin-18/M30 Antigen is Increased in the Cases with Impaired Glucose Tolerance
Beta cell death by apoptosis is an important mechanism in beta cell dysfunction and development of diabetes. Inhibition of apoptosis may be helpful approach in the prevention of diabetes. In this context, non-invasive, specific markers are needed to detect apoptosis in prediabetic stage. In the present study serum levels of cytokeratin-18/M30 antigen, a surrogate marker of apoptosis were investigated in cases with type 2 diabetes and İmpaired Glucose Tolerance (IGT).
- 31 December 2017
- Published by ClinMed International Library in International Archives of Endocrinology Clinical Research
- Vol. 3 (1)
Open AccessSerum Level of Cytokeratin-18/M30 Antigen is Increased in the Cases with Impaired Glucose Tolerance
Beta cell death by apoptosis is an important mechanism in beta cell dysfunction and development of diabetes. Inhibition of apoptosis may be helpful approach in the prevention of diabetes. In this context, non-invasive, specific markers are needed to detect apoptosis in prediabetic stage. In the present study serum levels of cytokeratin-18/M30 antigen, a surrogate marker of apoptosis were investigated in cases with type 2 diabetes and İmpaired Glucose Tolerance (IGT).